Leukemia after Adjuvant Chemotherapy with Semustine (Methyl-CCNU) — Evidence of a Dose–Response Effect
- 9 January 1986
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 314 (2) , 119-120
- https://doi.org/10.1056/nejm198601093140214
Abstract
To the Editor: We reported1 a high risk of leukemia and preleukemia among 2067 patients given adjuvant semustine (methyl-CCNU) and fluorouracil in any of nine randomized clinical trials for gastrointestinal cancer (relative risk, 16; incidence rate, 2.4 cases per 1000 persons per year). Subsequently, we abstracted detailed information on the cumulative drug dose for all 19 patients in whom a leukemic disorder developed and for a 15 percent sample (n = 317) of all patients who received chemotherapy. (Since our last report, one additional acute nonlymphocytic leukemia occurred in an 84-year-old woman with colon cancer who received 293 mg of . . .Keywords
This publication has 5 references indexed in Scilit:
- Combined-Modality Therapy of CancerNew England Journal of Medicine, 1985
- Leukemia and Preleukemia after Adjuvant Treatment of Gastrointestinal Cancer with Semustine (Methyl-CCNU)New England Journal of Medicine, 1983
- Acute Nonlymphocytic Leukemia after Therapy with Alkylating Agents for Ovarian CancerNew England Journal of Medicine, 1982
- Increased Incidence of Acute Leukemia in Polycythemia Vera Associated with Chlorambucil TherapyNew England Journal of Medicine, 1981
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958